| Class | Beta blocker |
|---|---|
| Chemistry |
aryloxypropanolamine |
| Routes of administration |
IV |
| Absorption |
0% oral bioavailability |
| Solubility |
pKa 9.5, minimal lipid solubility |
| Distribution |
VOD 3.4 L/kg; 60% protein bound |
| Metabolism |
rapidly metabolized in blood by hydrolysis of its methyl ester linkag |
| Elimination |
minimal renal excretion; half-life 9 min |
| Time course of action |
Rapid onset and offset of effect |
| Target receptor |
Highly selective β1 receptor blocker |
| Mechanism of action |
By binding to Gs-protein coupled β1 receptors, blocks cAMP synthesis |
| Clinical effects |
β1 effects: decreased heart rate, cdecreased contractility, decreased blood pressure, lower myocardial oxygen demand and increased diastolci coronary fillng, and decreased arrhythmogenicity. |
| Literature reference |
Oliver et al (2019) |
| CICM details of understanding | Level 2 |
| Mentioned around Deranged Physiology | |
| Related SAQs |
Question 5 from the first paper of 2022 (labetalol vs. esmolol) Question 14 from the second paper of 2019 (metoprolol vs esmolol) |